Chris Calcaterra - Glaukos Corp Chief Commercial Officer
| GKOS Stock | USD 142.69 1.96 1.39% |
Executive
Mr. Chris M. Calcaterra serves as Chief Operating Officer of the Company. Mr. Calcaterra served as our chief commercial officer from April 2008 until becoming our chief operating officer in February 2017. He has more than 30 years of experience in the ophthalmic medical technology industry. Prior to joining our Company, Mr. Calcaterra was senior vice president at Advanced Medical Optics, Inc., and was responsible for its cataract business. Prior to that position, Mr. Calcaterra held increasingly responsible vice president positions in a variety of sales and marketing roles at Advanced Medical Optics, Inc., as well as its predecessor surgical division business at Allergan, Inc since 2017.
| Age | 64 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 949 367 9600 |
| Web | https://www.glaukos.com |
Glaukos Corp Management Efficiency
The company has return on total asset (ROA) of (0.0774) % which means that it has lost $0.0774 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.261) %, meaning that it created substantial loss on money invested by shareholders. Glaukos Corp's management efficiency ratios could be used to measure how well Glaukos Corp manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Teryl Sides | SurModics | 54 | |
| Chris Williamson | Iradimed Co | N/A | |
| Steve Kachelmeyer | Iradimed Co | N/A | |
| Manohar Raheja | Sight Sciences | N/A | |
| Stephen JD | Sight Sciences | N/A | |
| Matt Brinckman | Paragon 28 | N/A | |
| Kimberly Lockwood | CONMED | N/A | |
| Matthew Jarboe | Paragon 28 | 41 | |
| Roberto Donadello | Orthofix Medical | N/A | |
| Randy Waddell | Iradimed Co | N/A | |
| Gordon Weber | SurModics | 61 | |
| Andres Cedron | Orthofix Medical | 43 | |
| Lynn Neuhardt | Iradimed Co | N/A | |
| Daniel JD | Orthopediatrics Corp | 54 | |
| Brenton Taylor | Sight Sciences | 43 | |
| John Harris | Integer Holdings Corp | 64 | |
| Trui Hebbelinck | LivaNova PLC | 52 | |
| Kashif JD | Nevro Corp | 50 | |
| Suzanne Armstrong | Orthofix Medical | N/A | |
| David MD | Nevro Corp | 67 | |
| Kashif Rashid | Nevro Corp | 50 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.0774 |
Glaukos Corp Leadership Team
Elected by the shareholders, the Glaukos Corp's board of directors comprises two types of representatives: Glaukos Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Glaukos. The board's role is to monitor Glaukos Corp's management team and ensure that shareholders' interests are well served. Glaukos Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Glaukos Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mory Gharib, CoFounder | ||
| Gilbert Kliman, Independent Director | ||
| Michele Allegretto, Senior Resources | ||
| Leana Wen, Independent Director | ||
| L Katz, Chief Medical Officer | ||
| Thomas Burns, Chairman of the Board, President, Chief Executive Officer | ||
| Robert Davis, General VP | ||
| Diane Biagianti, Sr Counsel | ||
| David Hoffmeister, Independent Director | ||
| David Haffner, VP Technologies | ||
| Mark Foley, Lead Independent Director | ||
| Denice Torres, Independent Director | ||
| William Link, Independent Chairman of the Board | ||
| Chris Calcaterra, Chief Commercial Officer | ||
| Joseph Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development | ||
| Christopher Lewis, Vice Affairs | ||
| Diana Scherer, VP Counsel | ||
| Alex Thurman, Chief Financial Officer, Senior Vice President | ||
| Tomas Navratil, Chief Development Officer | ||
| MD FACS, Chief Officer | ||
| Jane Rady, Senior Development | ||
| Aimee Weisner, Independent Director | ||
| Robert JD, General VP | ||
| Marc Stapley, Independent Director |
Glaukos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Glaukos Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.0774 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 7.65 B | ||||
| Shares Outstanding | 55.14 M | ||||
| Shares Owned By Insiders | 3.19 % | ||||
| Shares Owned By Institutions | 96.81 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Earning | 94.70 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.